FFAR3 and Hepatic steatosis: SCFAs including butyrate, acetate, and propionate have been reported to improve hepatic steatosis either by activating G protein-coupled receptor 41 (GPR41) and GPR43 receptors in adipose tissue, the intestine, and the liver, or by directly acting locally without binding to their receptors [23].